Company news

Ipsen SA news in 2025

Ipsen SA's news releases, calls and decks from 2025, newest first.

View company

Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate

December 22, 2025

Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)

December 19, 2025

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline

December 15, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 49- 2025

December 9, 2025

Ipsen provides update on legacy of Henri Beaufour

December 5, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 48 - 2025

December 2, 2025

Ipsen mourns the passing of Henri Beaufour, a founding family Board member

December 1, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 47 - 2025

November 25, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 46 - 2025

November 19, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 45 - 2025

November 12, 2025

Ipsen - October 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

November 7, 2025

Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue

November 7, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 44 - 2025

November 6, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 43 - 2025

October 28, 2025

EQT Life Sciences' ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion

October 22, 2025

Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance

October 22, 2025

Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline

October 22, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 42 - 2025

October 21, 2025

DETERA Therapeutics Wins the Ipsen Golden Ticket 2025

October 15, 2025

Ipsen - September 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

October 7, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2025

September 30, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2025

September 23, 2025

Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III

September 22, 2025

Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC

September 19, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2025

September 16, 2025

Ipsen - August 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

September 11, 2025

Health Canada Approves Bylvay™ (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille Syndrome

September 9, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2025

September 2, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2025

August 29, 2025

Ipsen - July 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

August 27, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 2025

August 19, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2025

August 12, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2025

August 5, 2025

Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance

July 31, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2025

July 29, 2025

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors

July 24, 2025

Ipsen announces changes to its Executive Committee

July 23, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2025

July 22, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2025

July 16, 2025

Ipsen - June 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

July 10, 2025

The Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal and IRICoR Announce initiation of Phase 1 Trial of Licensed Small Molecule Therapy for Solid Tumors

July 8, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2025

July 1, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2025

June 24, 2025

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

June 20, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2025

June 17, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2025

June 13, 2025

Ipsen - May 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

June 12, 2025

Ipsen S.A. - Initiation of the share buy-back program

June 2, 2025

Ipsen S.A. - Annual General Meeting held on 21 May 2025

May 21, 2025

Ipsen - April 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

May 12, 2025

Older news releases →

Calls in 2025

Decks in 2025